Bold takeaway: Parkinson’s research funding is being renewed to power a global effort that aims to repurpose existing drugs to slow or halt disease progression. And this is where it gets controversial: should we rely on repurposed meds with unproven disease-modifying effects, or push for entirely novel therapies? Here’s a deeper, beginner-friendly rewrite that preserves the core information, expands with clarity and engaging hooks.
Van Andel Institute (VAI) and Cure Parkinson’s have renewed a funding agreement to continue supporting the International Linked Clinical Trials Program, the world’s largest initiative dedicated to repurposing drugs for Parkinson’s disease.
Under the three-year pact, VAI and Cure Parkinson’s will each contribute $750,000 annually to the program. The organizations also plan to work together to raise additional funds to advance Parkinson’s clinical trials.
Darren Moore, Ph.D., who holds the Jay Van Andel Endowed Chair in Parkinson’s Disease Research at VAI and serves on the program’s Scientific Committee, expressed enthusiasm. He noted that the renewed collaboration will sustain the program’s efforts to identify promising therapies that could slow, halt, or modify the course of Parkinson’s and improve patients’ quality of life.
Helen Matthews, CEO of Cure Parkinson’s, highlighted the continued success of the partnership since 2014. She explained that the new matched funding could bring between $1.5 million and $1.75 million each year toward disease-modifying Parkinson’s research. This support will back clinical trials and related projects within the International Linked Clinical Trials initiative, a globally active program aimed at developing treatments to slow, stop, or reverse Parkinson’s.
Global context: an estimated 10 million people worldwide live with Parkinson’s disease, with numbers expected to rise as populations age. While current treatments help manage symptoms, there are no approved therapies proven to slow or stop disease progression.
What the program does: the International Linked Clinical Trials Program seeks to change the landscape by funding and coordinating clinical trials that evaluate potentially disease-modifying therapies for Parkinson’s. A substantial portion of the trial candidates are repurposed drugs—medications originally developed for other conditions. This strategy can save time and resources because these drugs have already undergone extensive safety and efficacy testing in other contexts.
Oversight and prioritization: a Scientific Committee made up of Parkinson’s researchers, clinicians, and advocates reviews and prioritizes medications for study. Approximately 40% of the drugs under consideration have been earmarked for clinical trials by the program.
Impact so far: to date, more than 6,800 people with Parkinson’s have participated in trials associated with the program. Of the 47 trials launched since its inception, 19 are ongoing and 28 have been completed. VAI has supported 10 of these trials through its funding.
Controversial note and invitation for discussion: while repurposing drugs accelerates the pathway to potential therapies, some critics argue that repurposed candidates may not offer meaningful disease modification or could introduce unforeseen risks. What counts as meaningful disease modification, and how should success be measured in these trials? Share your views in the comments: do you support a focus on repurposed drugs as a speedier route to progress, or do you favor more investment in novel, disease-modifying therapies with new mechanisms of action?
Source and cautions: this content summarizes program announcements and does not constitute medical advice. Always consult medical professionals for treatment decisions. Additionally, while every effort is made to present accurate information, verify details with the original sources.
